Can Ku-32 Drug Reverse Diabetic Peripheral Neuropathy Pain?

The nerves which connect the central nervous system to the limbs and organs are called the peripheral nerves. They are located outside the brain and spinal cord. People suffering from diabetes for long time experience a pain owing to a condition called diabetic peripheral neuropathy, or DPN. It involves damage of peripheral nerves and pain as high blood sugar levels persist for years.

Researchers at the University of Kansas developed a drug which can reduce the pain associated with this condition. Though the drug is in its early stages of clinical development, tried only on experimental mice, greater implications await in future. It may take two more years for the drug KU-32 to be tried on humans.

More results of the study were published in September 2010 issue of the American Society of Neurochemistry’s journal, ASN Neuro. It was funded by grants from the Juvenile Diabetes Research Foundation and the National Institutes of Health.

What Research Learnt About the Diabetic Peripheral Neuropathy (DPN) Pain Drug?

  • DPN is a condition which causes the death of nerves in diabetic patients.
  • As a result, a great pain is felt by these patients even for a light touch.
  • Loss of feeling is also experienced in the hands and feet which makes these individuals be prone to wounds and infections.
  • They grow in severity quickly and often lead to amputation of the organs, After injuries, DPN is the second leading cause of amputating body organs.
  • The researchers found that DPN was treated by KU-32 drug by inhibiting a type of proteins known as the molecular chaperones associated with nerve damage.
  • The drug infect was effective in even reversing the DPN condition when tried on experimental mice in laboratory.

Significance of the Research on Diabetic Peripheral Neuropathy (DPN) Pain Drug:
60 percent of the 24 million American diabetic patients are affected with DPN. Two FDA approved drugs available for treatment this condition are antidepressent and anticonvulsant with neither of them possesing the ability to reverse the condition.

KU-32 drug apart from its DPN-reversing ability can be taken orally once every week. It is found to be without any toxins, easily dissolved in blood, with less side effects.

Even the dosage of the drug required will be less owing to its long-trem efficacy. Further research is focussed on knowing the stage at which this dtug should be given to the patient to ensure maximum efficacy against DPN.

Leave a reply

Your email address will not be published. Required fields are marked *